Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058621 | 1.00 | FPR2 (0.38) | FPR2PROKR1MMP1HCRTR1HCRTR2 | |
| SCHEMBL12849163 | 0.82 | FPR2 (0.37) | FPR2PROKR1MMP1HCRTR1HCRTR2 | |
| SCHEMBL12237054 | 0.79 | HCRTR2 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL12237056 | 0.78 | TRPC3 (0.33) | — | |
| SCHEMBL14534932 | 0.78 | MMP1 (0.38) | FPR2PROKR1MMP1HCRTR1HCRTR2 | |
| SCHEMBL21652006 | 0.76 | FPR2 (0.47) | FPR2PROKR1MMP1HCRTR1RET | |
| SCHEMBL12237060 | 0.73 | ALDH1A1 (0.44) | — | |
| SCHEMBL14877536 | 0.73 | FPR2 (0.43) | FPR2PROKR1MMP1HCRTR1HCRTR2 | |
| SCHEMBL12827220 | 0.72 | NPC1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL12849164 | 0.71 | SLC6A2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | FPR2 4187/4885PROKR1 2519/4885MMP1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.